OPKO Health (OPK) Q2 FY26 earnings call

OPKO Health delivered improved profitability in Q2 FY26, driven by operational efficiencies in its Diagnostics segment and strong performance in its Pharmaceutical business. The company continues to advance a robust pipeline across oncology, immunology, and metabolic diseases, including a promising in vivo CAR-T program and a GLP-1 glucagon candidate. While certain diagnostic growth initiatives face near-term delays, management remains focused on pipeline progression and sustainable cash flow generation.